Table 2.
Agent | Phase | Status | Study Type | Description |
---|---|---|---|---|
Bevacizumab | Clinicaltrials.gov search retrieves records for 3 phase 1 trials 2 phase 1/2 trials 11 phase 2 trials 1 phase 3 trial | The phase 1, 1/2, and 2 trials are completed or ongoing The phase 3 trial is recruiting | Several | The early-phase trials are exploring several different regimens The phase 3 trial is a multicenter, randomized, controlled trial in which patients with recurrent or metastatic HNSCC receive chemotherapy ± bevacizumab. Chemotherapy consists of cisplatin, docetaxel, and fluorouracil. |
| ||||
anti-CD45 MAb | 1 (NCT00608257) | Completed (N = 18) | Dose-escalation study | Patients with EBV-positive nasopharyngeal cancer receive autologous EBV-specific cytotoxic T cells in combination with anti-CD45 MAb |
| ||||
MN-14 (anti-CEA MAb) | 1/2 (NCT00004048) | Active, not recruiting(N ~ 30) | Dose-escalation study | Patients with medullary thyroid cancer undergo radioimmunotherapy with MN-14 alone or combined with doxorubicin and peripheral blood stem cell rescue |
CEA: carcinoembryonic antigen; EBV: Epstein-Barr virus; HNSCC: head and neck squamous cell carcinoma; MAb: monoclonal antibody.